Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016)

Niagen Bioscience (NAGE) has disclosed Liabilities from Discontinued Operations for 1 consecutive years, with 184766.0 as the latest value for Q4 2016.

  • On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 184766.0 in Q4 2016 year-over-year; TTM through Dec 2016 was 184766.0, a N/A change, with the full-year FY2016 number at 184766.0, changed N/A from a year prior.
  • Liabilities from Discontinued Operations was 184766.0 for Q4 2016 at Niagen Bioscience.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 184766.0 in Q4 2016 to a low of 184766.0 in Q4 2016.